Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/39475
Title: Intravascular ultrasound guidance improves clinical outcomes during implantation of both first-and secondgeneration drug-eluting stents: A meta-analysis.
Authors: Brown A.J.;Ihdayhid A.-R.;McCormick L.M.;Cameron J.D.;Bennett M.R.;Malaiapan Y.;Meredith I.T. ;Nerlekar N. ;Cheshire C.J.;Verma K.P.
Institution: (Nerlekar, Cheshire, Verma, Ihdayhid, McCormick, Cameron, Malaiapan, Meredith, Brown) Monash Cardiovascular Research Centre and MonashHeart, Monash Health, Clayton, VIC 3168, Australia (Bennett, Brown) Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
Issue Date: 10-Apr-2017
Copyright year: 2017
Publisher: EuroPCR
Place of publication: France
Publication information: EuroIntervention. 12 (13) (pp 1632-1642), 2017. Date of Publication: 2017.
Journal: EuroIntervention
Abstract: Aims: Our aim was to assess whether intravascular ultrasound (IVUS) improves clinical outcomes during implantation of first-and second-generation drug-eluting stents (DES). IVUS guidance is associated with improved clinical outcomes during DES implantation, but it is unknown whether this benefit is limited to either first-or second-generation devices. Methods and Results: MEDLINE, EMBASE and PubMed were searched for studies comparing outcomes between IVUS-and angiography-guided PCI. Among 909 potentially relevant studies, 15 trials met the inclusion criteria. The primary endpoint was MACE, defined as death, myocardial infarction, target vessel/ lesion revascularisation (TVR/TLR) or stent thrombosis (ST). Summary estimates were obtained using Peto modelling. In total, 9,313 patients from six randomised trials and nine observational studies were included. First-generation DES were implanted in 6,156 patients (3,064 IVUS-guided and 3,092 angiography-guided) and second-generation in 3,157 patients (1,528 IVUS-guided and 1,629 angiography-guided). IVUS guidance was associated with a significant reduction in MACE (odds ratio [OR] 0.73, 95% CI: 0.64-0.85, p<0.001), across both first-(OR 0.79, 95% CI: 0.67-0.92, p=0.01) and second-generation DES (0.57, 95% CI: 0.43-0.77, p<0.001). For second-generation DES, IVUS guidance was associated with significantly lower rates of cardiac death (OR 0.33, 95% CI: 0.14-0.78, p=0.02), TVR (OR 0.47, 95% CI: 0.28-0.79, p=0.006), TLR (OR 0.61, 95% CI: 0.42-0.90, p=0.01) and ST (OR 0.31, 95% CI: 0.12-0.78, p=0.02). Cumulative meta-analysis highlighted progressive temporal benefit towards IVUS-guided PCI to reduce MACE (OR 0.60, 95% CI: 0.48-0.75, p<0.001). Conclusion(s): IVUS guidance is associated with a significant reduction in MACE during implantation of both first-and second-generation DES platforms. These data support the use of IVUS guidance in contemporary revascularisation procedures using second-generation DES.Copyright © Europa Digital & Publishing 2017. All rights reserved.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.4244/EIJ-D-16-00769
Link to associated publication: Click here for full text options
PubMed URL: 27840327 [http://www.ncbi.nlm.nih.gov/pubmed/?term=27840327]
ISSN: 1774-024X
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/39475
Type: Article
Subjects: paclitaxel eluting coronary stent
percutaneous coronary intervention
randomized controlled trial (topic)
sirolimus eluting coronary stent
stent thrombosis/co [Complication]
*intravascular ultrasound
systematic review
medical device complication/co [Complication]
meta analysis
observational study
coronary angiography
coronary artery disease/dt [Drug Therapy]
*coronary stenting
*drug eluting coronary stent
everolimus eluting coronary stent
heart death/co [Complication]
heart infarction/co [Complication]
heart muscle revascularization
human
zotarolimus eluting coronary stent
everolimus/dt [Drug Therapy]
paclitaxel/dt [Drug Therapy]
rapamycin/dt [Drug Therapy]
zotarolimus/dt [Drug Therapy]
*drug eluting coronary stent/am [Adverse Device Effect]
everolimus eluting coronary stent/am [Adverse Device Effect]
paclitaxel eluting coronary stent/am [Adverse Device Effect]
sirolimus eluting coronary stent/am [Adverse Device Effect]
zotarolimus eluting coronary stent/am [Adverse Device Effect]
article
cardiovascular disease/co [Complication]
*clinical outcome
systematic review
Article
cardiovascular disease / complication
*clinical outcome
coronary angiography
coronary artery disease / drug therapy
*coronary stenting
*drug eluting coronary stent
everolimus eluting coronary stent
heart death / complication
heart infarction / complication
heart muscle revascularization
human
*intravascular ultrasound
medical device complication / complication
meta analysis
observational study
paclitaxel eluting coronary stent
percutaneous coronary intervention
randomized controlled trial (topic)
sirolimus eluting coronary stent
stent thrombosis / complication
zotarolimus eluting coronary stent
Type of Clinical Study or Trial: Systematic review and/or meta-analysis
Appears in Collections:Articles

Show full item record

Page view(s)

22
checked on Aug 16, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.